CHICAGO (EGMN) - A string of disappointing melanoma trials from the Eastern Cooperative Oncology Group left some seeing the proverbial glass as half empty, others as half full in an oral abstract session at the annual meeting of the American Society for Clinical Oncology. No Benefit from GM-CSF Updated data from the E4697 phase III cooperative trial in resected stage III and IV melanoma show only a hint of benefit for granulocyte-macrophage colony-stimulating factor (GM-CSF) in...